Virtual Reality Relaxation Outperforms Traditional Relaxation in Palliative Care
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 31, 2024 -- Flourishing-Life-Of-Wish Virtual Reality Therapy (FLOW-VRT)-Relaxation, which has a special focus on relaxation, outperforms traditional relaxation for patients in palliative care, according to a study published online Jan. 31 in Frontiers in Virtual Reality.
Olive Kit Ling Woo, from the University of Hong Kong, and colleagues presented a structured, personalized, and innovative psychological intervention, FLOW-VRT, which makes use of VRT for symptom management. FLOW-VRT-Relaxation was designed for patients in need of palliative care to enhance end-of-life coping through personalized VR relaxation. The efficacy of FLOW-VRT-Relaxation was examined by comparing it to traditional relaxation practice in palliative care in a randomized trial involving 128 participants.
The researchers found that the symptoms of distress, physical or emotional in nature, which patients in palliative care have to endure, were significantly reduced following a FLOW-VRT-Relaxation session.
"Here we show that relaxation assisted by virtual reality outperforms traditional relaxation therapy in terms of physical and psychological symptom management in palliative care," Woo said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-02-01 04:15
Read more
- Neurological Outcomes Worsen With Gestational HTN, Preeclampsia, Eclampsia
- Sex Disparities Identified in Natural History of Tourette Syndrome
- Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
- Gender-Affirming Medication Use Rare in U.S. Transgender Adolescents From 2018 to 2022
- Supreme Court to Decide on South Carolina's Bid to Cut Funding for Planned Parenthood
- Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions